# Aethlon Medical, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Aethlon Medical, Inc). ## Overview Aethlon Medical, Inc. is a San Diego-based medical therapeutic company developing the Hemopurifier®, a clinical-stage extracorporeal immunotherapeutic device designed to remove enveloped viruses and harmful extracellular vesicles (EVs) from biological fluids using a proprietary lectin-based mechanism. The company is targeting applications in cancer, life-threatening viral infections, and organ transplantation—areas where clinical adoption depends on human study outcomes and regulatory clearance. The FDA has designated the Hemopurifier as a Breakthrough Device for two independent indications, positioning the program for potentially accelerated regulatory interaction but not reducing the need for robust clinical evidence. Aethlon remains pre-commercial and its near-term business model is centered on advancing clinical trials, securing manufacturing readiness, and building the reimbursement and clinical-use case required for hospital adoption. ## Products & services • Hemopurifier® immunotherapeutic blood filtration device • Lectin-based affinity capture cartridge/technology platform • Clinical studies in viral infection indications (e.g., Ebola case use) • Oncology-focused applications targeting EV-mediated disease pathways • Organ transplantation applications (adjunct immune modulation concept) • IP portfolio and trademarks (Hemopurifier, Aethlon ADAPT™, ELLSA™) - **Hemopurifier device program** (80%) — Core clinical-stage extracorporeal device and single-use components intended to remove viruses and EVs. - **Clinical development and regulatory activities** (15%) — Human studies, preclinical research, and FDA/foreign regulatory work to support future clearance. - **Intellectual property and platform extensions** (5%) — Patents, trademarks, and potential new indications leveraging the lectin-based mechanism. - Hemopurifier® immunotherapeutic blood filtration device - Lectin-based affinity capture cartridge/technology platform - Clinical studies in viral infection indications (e.g., Ebola case use) - Oncology-focused applications targeting EV-mediated disease pathways - Organ transplantation applications (adjunct immune modulation concept) - IP portfolio and trademarks (Hemopurifier, Aethlon ADAPT™, ELLSA™) ## Customers As a clinical-stage company, Aethlon’s near-term “customers” are primarily clinical trial sites and investigators that evaluate the Hemopurifier in human studies, alongside regulators that determine the pathway to commercialization. If cleared for use, the company expects primary purchasers to be medical institutions (hospitals and transplant/oncology centers) that would use the device in procedures and then seek reimbursement from third-party payors. Adoption would depend on demonstrated clinical benefit, workflow fit with extracorporeal treatment settings, and the availability and adequacy of reimbursement from CMS and private insurers. The company also relies on third-party manufacturers and suppliers as critical ecosystem partners because scaling production and meeting good manufacturing practices are prerequisites to serving hospital demand. - **Hospitals and medical institutions** (primary) — Would purchase Hemopurifier treatments/devices if cleared, driven by clinical outcomes and reimbursement feasibility. - **Oncology and cancer treatment centers** (secondary) — Potential users where EV removal could support treatment strategies tied to immune suppression and metastasis. - **Infectious disease and critical care providers** (secondary) — Potential users for life-threatening viral infections where rapid viral/EV reduction could be clinically meaningful. - **Transplant centers** (emerging) — Potential users in organ transplantation settings as an adjunct immunotherapeutic approach. - Hospitals and medical institutions (future buyers) for procedure-based use - Oncology centers seeking adjunct approaches to immune suppression/metastasis - Infectious disease and critical care units for severe viral infections - Transplant centers for organ transplantation-related applications - Third-party payors (CMS/private insurers) influence adoption via reimbursement - Clinical trial sites and investigators generating human study evidence ## Geography Aethlon Medical is headquartered in San Diego, California and is incorporated in Nevada, with U.S. operations driving corporate management and R&D oversight. The company’s commercialization plans contemplate both U.S. and international markets, but foreign market entry would require successful human trials and approvals by non-U.S. regulatory agencies. The firm has demonstrated at least limited international clinical use under emergency conditions (e.g., a single-patient Ebola emergency use at Frankfurt University Hospital in Germany), indicating potential global clinical interest but not established commercial presence. Geopolitical and macro conditions (inflation, bank failures, and conflicts including Russia–Ukraine and Israel and surrounding areas) are monitored primarily for their impact on capital markets, timelines, and access to financing rather than for current revenue exposure. - Executive offices in San Diego, California (operational and R&D hub) - Incorporated in Nevada; listed on Nasdaq Capital Market (AEMD) - International regulatory approvals required for non-U.S. commercialization - Emergency-use clinical experience referenced in Germany (Frankfurt hospital) - Macro/geopolitical shocks mainly affect funding access and trial timelines - Trademark footprint includes EU/UK/India via Madrid registration strategy ## Strategy The company’s strategy centers on advancing the Hemopurifier through clinical development to generate human data that can support regulatory clearance and clinical adoption in targeted indications. Aethlon is also focused on maintaining and extending its proprietary position through patents and trademarks around the Hemopurifier and related platform concepts (e.g., Aethlon ADAPT™ and ELLSA™). Because future competitiveness depends on reliable supply and cost-effective production, building relationships and capabilities for GMP-compliant manufacturing and qualifying critical materials are strategic necessities. Finally, the company’s commercialization planning implicitly depends on establishing reimbursement pathways, as hospitals are expected to bill CMS and private payors for procedures using the device. - **Generate clinical evidence in targeted indications** (short-term) — Human data is required to gain regulatory clearance and clinician support for a clinical-stage device. - **Advance regulatory pathway leveraging Breakthrough Device status** (medium-term) — Regulatory progress is gating for commercialization and partnering/manufacturing scale-up decisions. - **Manufacturing readiness and supply chain robustness** (medium-term) — Commercial viability requires scalable production, qualified materials, and compliance with good manufacturing practices. - Run human clinical studies to prove safety/efficacy and drive adoption - Leverage FDA Breakthrough Device designation to support regulatory pathway - Expand indications (cancer, viral infections, transplantation) to widen TAM - Secure GMP-compliant manufacturing and qualify key materials/suppliers - Build reimbursement case for CMS/private payors to enable hospital uptake - Protect platform via patents and trademarks (Hemopurifier, ADAPT, ELLSA) ## Risks Aethlon faces development-stage risk: the Hemopurifier is not yet commercialized and its prospects depend on successful clinical trials and regulatory clearance in the U.S. and abroad. The company discloses substantial financing risk, including ongoing losses and the need for additional capital that could dilute existing shareholders, with macro shocks (inflation, bank failures, geopolitical conflicts) potentially tightening capital availability and extending timelines. Operationally, the device relies on third-party suppliers and manufacturing partners; delays, interruptions, or failure to meet GMP requirements can prevent or delay production and trials. Even with clearance, reimbursement risk is significant because hospital purchasing is closely tied to CMS/private payor coverage decisions and health technology assessments, and the technology could be displaced by more effective or economical competing modalities (including competing blood filters). - **Ongoing losses and need for additional capital** [critical] — The company expects to continue incurring losses and requires financing to sustain operations and trials, which may dilute shareholders. - **Manufacturing and supplier dependency** [high] — Delays/interruptions by third-party suppliers or delays qualifying materials can prevent or delay Hemopurifier manufacturing. - **Regulatory approval and agency capacity risk** [high] — Failure to comply with extensive regulations or inadequate funding/staffing at FDA/foreign agencies could delay or prevent commercialization. - **Reimbursement and coverage risk** [high] — Hospitals rely on third-party payors; CMS coverage requires demonstrating treatment is reasonable and necessary and the process is lengthy and expensive. - **Technology obsolescence and competitive displacement** [high] — New scientific developments or better/economical competing products could render the Hemopurifier unmarketable; competitors include ExThera blood filters. - Need for additional financing; dilution risk and funding availability shocks - Clinical trial failure or delays could block regulatory clearance - Regulatory compliance burden in U.S. and foreign markets - Third-party supplier/manufacturing disruptions can halt device availability - Reimbursement may be unavailable or insufficient (CMS/private payors) - Technology obsolescence from new modalities or competing blood filters - Key-person dependency in scientific/medical management roles - Government agency resource constraints (e.g., FDA funding) may slow reviews ## Accounting Aethlon’s financial statements rely on management estimates typical of a clinical-stage medical device developer, where expenses and liabilities can shift based on trial activity and financing actions. The company identifies critical estimates around long-lived assets, stock-based compensation, valuation allowance for deferred tax assets, contingencies, and clinical trial accruals—each of which can materially affect reported operating expenses and net loss. Equity-linked financing features can add complexity: warrant inducement transactions require judgment to determine whether modifications represent a substantive inducement and, if so, to measure and expense the incremental fair value in the period. Investors should also expect quarter-to-quarter volatility in operating expenses driven by payroll, professional fees, and the timing of clinical and regulatory work rather than by recurring product revenue. - **Clinical trial accruals** — Can cause operating expense volatility and revisions to accrued liabilities - **Stock-based compensation** — Non-cash expense that can materially affect reported loss - **Valuation allowance for deferred tax assets** — Impacts income tax provision/benefit and balance sheet presentation - **Warrant inducement transactions** — May result in incremental expense recognized in the transaction period - Clinical trial accrual estimates can shift with site activity and timelines - Stock-based compensation affects operating expense and is estimate-driven - Deferred tax valuation allowance reflects judgment on future profitability - Contingencies require judgment on probability and estimable losses - Long-lived asset lives/impairment judgments affect depreciation/impairment - Warrant inducement accounting may create non-cash expense volatility - Fair value estimates for inducements depend on assumptions and timing --- *Last updated: 2026-08-11T04:46:17.268614+00:00*